Does Oscar Health Cover Dupixent?

What Dupixent Is and Why Coverage Is Complicated

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor subunit for interleukin-4 and interleukin-13, two cytokines central to type-2 inflammation. The FDA first approved dupilumab in March 2017 for adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. [1] Since then, the agency has expanded the label to cover severe asthma with an eosinophilic phenotype or oral corticosteroid dependence, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), and prurigo nodularis. [2]

Why Biologics Sit in a Special Coverage Category

Specialty drugs like Dupixent occupy the highest tiers on virtually every commercial formulary because their wholesale acquisition costs are orders of magnitude above conventional therapies. The Institute for Clinical and Economic Review (ICER) has published multiple analyses examining whether dupilumab's clinical benefit justifies its price, specifically in atopic dermatitis and asthma populations. [3] Oscar Health, as a commercially operated ACA-compliant and employer-sponsored insurer, mirrors industry norms by placing Dupixent on a Tier 4 or Tier 5 specialty rung and requiring prior authorization.

FDA Label Scope That Oscar Recognizes

Oscar's medical policies for biologics typically follow FDA-labeled indications. The current Dupixent prescribing information lists: moderate-to-severe atopic dermatitis in patients aged 6 months and older whose disease is not adequately controlled with topical therapies; add-on maintenance therapy for moderate-to-severe asthma aged 6 years and older; add-on maintenance therapy for CRSwNP in adults; EoE in patients aged 12 years and older weighing at least 40 kg; and prurigo nodularis in adults. [2] Off-label requests face a materially higher denial rate and require stronger supporting literature for a successful appeal.

How Oscar Health's Prior Authorization Process Works

Prior authorization (PA) is the single biggest barrier between a Dupixent prescription and the pharmacy dispensing the drug. Oscar follows a structured clinical review that mirrors criteria published by major professional societies, including the American Academy of Dermatology (AAD) guidelines for atopic dermatitis. [4]

Step 1: Prescriber Submits a PA Request

Your dermatologist, allergist, pulmonologist, or gastroenterologist submits a PA request through Oscar's provider portal or via fax. The request must include:

• ICD-10 diagnosis code matching an FDA-labeled Dupixent indication
• Documentation of disease severity (EASI score, IGA score, spirometry values, nasal endoscopy findings, or esophageal biopsy results depending on indication)
• Evidence of step therapy completion (topical corticosteroids, calcineurin inhibitors, or systemic immunosuppressants tried and failed, or contraindicated)
• Current medications and any documented adverse effects to prior agents

Step 2: Oscar's Clinical Review

Oscar routes PA requests to its pharmacy benefit manager (PBM) clinical team. Standard review takes 3 to 14 business days. Urgent review, triggered when a patient's condition places them at immediate clinical risk, must be completed within 72 hours under ACA regulations. The reviewer evaluates whether the submitted documentation meets Oscar's clinical criteria, which align with AAD evidence-based guidelines stating that dupilumab is recommended for patients with moderate-to-severe atopic dermatitis who fail topical therapy. [4]

Step 3: Approval, Denial, or Request for Additional Information

Oscar issues one of three responses. An approval authorizes dispensing through a specialty pharmacy (typically a 90-day supply). A request for additional information (RFAI) pauses the clock until your provider supplies missing clinical data. A denial triggers your right to appeal under federal and state law.

Step Therapy Requirements for Each FDA Indication

Step therapy (also called "fail first") requires documented inadequate response to one or more cheaper agents before Oscar will approve a biologic. Requirements differ by indication.

Atopic Dermatitis

For moderate-to-severe atopic dermatitis, Oscar generally requires documented failure of at least one medium-to-high-potency topical corticosteroid used for a minimum of 4 to 8 weeks, consistent with the 2023 AAD atopic dermatitis guideline update. [4] Some Oscar plans also require a trial of a topical calcineurin inhibitor such as tacrolimus 0.1% ointment. Systemic step therapy (methotrexate, cyclosporine) may be required on certain employer-sponsored plans with stricter formulary management. Cyclosporine at 3 to 5 mg/kg/day has historically been used off-label for severe AD, though its long-term nephrotoxicity profile often justifies skipping to a biologic. [5]

Asthma

For severe eosinophilic asthma, Oscar's PA criteria typically require: confirmed diagnosis of moderate-to-severe persistent asthma; blood eosinophil count of 150 cells per microliter or higher (some plans use 300 as a threshold for faster approval); and documented inadequate control on medium-to-high dose inhaled corticosteroids plus at least one additional controller. The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated that dupilumab 200 mg and 300 mg every 2 weeks reduced severe exacerbation rates by 47.7% and 48.0% respectively versus placebo over 52 weeks. [6] Presenting this trial data in a PA submission or appeal letter can strengthen the clinical argument.

CRSwNP

For chronic rhinosinusitis with nasal polyps, Oscar typically requires prior or concurrent intranasal corticosteroid use and documented polyp burden on CT or nasal endoscopy. The SINUS-24 and SINUS-52 trials showed dupilumab 300 mg every 2 weeks produced a 51% reduction in nasal polyp score versus 4% with placebo at 24 weeks (P<0.001). [7]

Eosinophilic Esophagitis

For EoE in patients aged 12 and older weighing at least 40 kg, Oscar may require a documented biopsy showing at least 15 eosinophils per high-power field and failure of a proton pump inhibitor (PPI) trial of at least 8 weeks. The key EoE trial (LIBERTY-EoE TREET, N=321) found dupilumab 300 mg weekly reduced peak eosinophil count from roughly 90 to fewer than 6 per high-power field in 59.5% of patients at week 24 versus 5.9% with placebo. [8]

What You Will Actually Pay With Oscar Coverage

Even after approval, your out-of-pocket cost depends on your specific Oscar plan's deductible, specialty drug copay structure, and whether you have met your out-of-pocket maximum.

Typical Oscar Plan Cost Structure

Most Oscar plans place Dupixent in a specialty tier with a coinsurance rate of 20% to 40% rather than a fixed copay. On a plan with a $4,500 annual out-of-pocket maximum (common on ACA silver-tier plans), once you hit that cap, Dupixent is covered at 100% for the rest of the benefit year. Before hitting the cap, monthly coinsurance on a roughly $3,900 wholesale acquisition cost drug can run $780 to $1,560 per fill.

Dupixent MyWay Copay Assistance

Sanofi and Regeneron offer the Dupixent MyWay program, which reduces commercial insurance copays to as low as $0 per month for eligible patients. Patients on government insurance (Medicare Part D, Medicaid, CHIP, TRICARE) do not qualify for copay cards under federal anti-kickback rules. For Oscar members with commercial or employer-sponsored plans, applying to Dupixent MyWay before the first fill is standard financial practice. Enrollment takes approximately 10 to 15 minutes online or by phone at 1-844-DUPIXENT.

Patient Assistance for Uninsured or Underinsured Patients

If Oscar denies coverage and appeals are exhausted, Sanofi's Dupixent patient assistance program provides the drug at no cost to patients below 600% of the federal poverty level who lack adequate insurance. [9]

How to Appeal a Dupixent Denial From Oscar Health

A denial is not a final answer. Under the ACA and the Employee Retirement Income Security Act (ERISA), you have a federally protected right to appeal. Published data suggest biologic prior authorization appeals succeed in approximately 40% of cases at the internal appeal level. [10]

Internal Appeal

You have 180 days from receipt of a denial notice to file an internal appeal with Oscar. Your appeal package should include:

• A detailed letter of medical necessity from your prescribing physician, referencing specific clinical scores and trial data
• Peer-reviewed publications supporting Dupixent for your specific indication
• Photographs (for atopic dermatitis) or objective test results documenting severity
• Records of all step therapy attempts with start dates, doses, durations, and outcomes

The AAD and American College of Allergy, Asthma and Immunology (ACAAI) both publish position statements supporting dupilumab as the standard of care for refractory type-2 inflammatory diseases, and these position statements can be attached as supporting literature. [11]

External Independent Review

If Oscar upholds the denial at the internal level, you may request an external independent review organization (IRO) review. IRO decisions are binding on the insurer in most states. The external reviewer is a board-certified clinician with no financial relationship to Oscar. Studies examining IRO outcomes for specialty drugs show reversal rates of 30% to 60% depending on the condition and clinical documentation quality. [10]

State Insurance Commissioner Complaint

Filing a complaint with your state's insurance department (for example, the New York Department of Financial Services if you are an Oscar member in New York) creates a regulatory record and sometimes accelerates reconsideration. Oscar is licensed in multiple states including New York, California, Texas, Florida, and others, each with its own consumer protection statutes.

Clinical Evidence Supporting Dupixent Coverage Arguments

When building a PA or appeal file, citing the published trial data directly makes a material difference. Oscar's clinical reviewers evaluate whether the evidence meets the standard for medical necessity.

Atopic Dermatitis Key Trials

The SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every 2 weeks produced IGA 0 or 1 (clear or almost clear skin) in 36% to 38% of patients at week 16 versus 8% to 10% with placebo. [12] A 52-week extension study (CHRONOS, N=740) confirmed durability, with 39% of patients on dupilumab plus topical corticosteroids achieving IGA 0/1 versus 12% on topical corticosteroids alone. [13]

Atopic Dermatitis in Children and Adolescents

The FDA expanded approval to children aged 6 to 11 in 2020 and to infants aged 6 months to 5 years in 2022, both based on controlled trials showing comparable efficacy and safety to adult studies. The pediatric trial in patients aged 6 to 11 (N=367) showed 33% achieving IGA 0/1 at week 16 with dupilumab 300 mg every 4 weeks versus 11% with placebo (P<0.001). [14] Oscar's pediatric PA criteria mirror these age-specific label expansions.

Oscar-Specific Tips From the HealthRX Clinical Team

The following considerations are drawn from patterns seen across dupilumab PA submissions on commercial plans similar to Oscar's formulary structure.

Get your EASI or IGA score documented at every visit. Oscar's reviewers look for objective scoring tools. A note that says "severe eczema" is far weaker than one citing an EASI score of 30 or an IGA of 3.

Request a peer-to-peer review. Oscar allows the prescribing physician to speak directly with the reviewing clinician. Dermatologists and allergists who invoke peer-to-peer within 5 business days of a denial often achieve reversal at that stage, before a formal appeal is needed.

Submit step therapy documentation proactively. Do not wait for Oscar to ask. Include pharmacy records showing fills, dates, and quantities for all prior topical or systemic agents tried. A prior authorization submitted with complete step therapy documentation at initial submission is approved significantly faster.

Check plan-year timing. If a patient is close to meeting their out-of-pocket maximum from other medical spending, pushing for Dupixent approval in the same benefit year converts a high-cost specialty tier drug into a zero-cost drug for the remaining months.

Use the Dupixent MyWay bridge supply. While a PA appeal is pending, Sanofi can provide a short-term bridge supply of Dupixent at no cost. Ask your prescriber to contact the Dupixent MyWay program (1-844-DUPIXENT) to arrange bridge doses.

Conditions Where Oscar May Deny Dupixent Coverage

Oscar is more likely to deny Dupixent when:

• The diagnosis is off-label (for example, alopecia areata, which remains investigational and is not FDA-approved for dupilumab as of early 2025)
• Step therapy documentation is absent or incomplete
• The severity threshold is not met (mild atopic dermatitis with IGA 1 is not a labeled indication)
• The patient is on a narrow-network or HMO plan where the prescribing specialist is out-of-network

For alopecia areata specifically, the FDA approved baricitinib (Olumiant) in June 2022 as the first systemic treatment, and ritlecitinib (Litfulo) in 2023 for patients aged 12 and older. [15] If a prescriber submits Dupixent for alopecia areata, Oscar will almost certainly deny on lack of FDA approval for that indication, and no clinical appeal is likely to succeed unless the patient is enrolled in a clinical trial or there is extraordinary clinical justification.

Specialty Pharmacy Logistics After Approval

Once Oscar approves a Dupixent PA, the drug is dispensed through a specialty pharmacy, not a standard retail pharmacy. Oscar works with specialty pharmacies including CVS Specialty, Walgreens Specialty, and Accredo. The specialty pharmacy will contact you to schedule delivery, complete a clinical intake, and confirm storage instructions. Dupixent must be stored in the refrigerator at 36 to 46 degrees Fahrenheit and can be kept at room temperature for up to 14 days. [2]

The specialty pharmacy also handles PA renewals, which Oscar typically requires every 12 months. Your prescriber must resubmit documentation confirming ongoing clinical response and medical necessity at each renewal cycle.